PARP 抑制剂联合安罗替尼作为卵巢癌装甲 CAR-T 细胞的桥接治疗可增强浸润与抗肿瘤疗效
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.
肿瘤细胞治疗研究
ALL SOURCES
把在研试验和前沿论文合在一起看,按时间倒序排列。本页条数 = 前沿论文 + 临床试验两块之和(导航里的「临床试验」板块只收在招的那部分,不另计入)。
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.
Integrative Multi-Omics Analysis Reveals a Mitochondrial-Immune Axis Associated With Neoadjuvant Chemotherapy Response in High-Grade Serous Ovarian Ca
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。